Hanna G G, Murray L, Patel R, Jain S, Aitken K L, Franks K N, van As N, Tree A, Hatfield P, Harrow S, McDonald F, Ahmed M, Saran F H, Webster G J, Khoo V, Landau D, Eaton D J, Hawkins M A
Centre for Cancer Research and Cell Biology, Queen's University of Belfast, Belfast, UK.
Department of Clinical Oncology, St James's Institute of Oncology, Leeds Cancer Centre, Leeds, UK.
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):5-14. doi: 10.1016/j.clon.2017.09.007. Epub 2017 Oct 13.
Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally.
目前，英国有六项关于立体定向消融放疗（SABR）的研究正在进行。其中许多研究涉及身体不同部位寡转移疾病的治疗。所有试验管理小组的成员共同合作，就合适的危及器官剂量限制制定了一份共识文件。利用当前研究的数据更新了现有但较旧综述中的数值。希望这种统一的方法将促进SABR在英国的标准化实施，并能够在SABR研究之间以及国际上进行有意义的毒性比较。
